文献速递肿瘤 PET/CT核素与放射性配体治疗

血流-代谢比值可能预测局部晚期食管鳞状细胞癌患者的治疗反应和生存

The flow-metabolism ratio might predict treatment response and survival in patients with locally advanced esophageal squamous cell carcinoma.
PubMed 文献 · EJNMMI Res · 2020-05-29

本前瞻性研究纳入27例经病理证实的食管鳞状细胞癌患者,在根治性放化疗前分别行灌注CT和18F-FDG PET/CT,计算血流-代谢比值(FMR,即BF除以SUVmax)。结果显示,FMR与治疗反应及生存相关,低FMR患者生存更差,FMR是OS和PFS的独立预测因素。

要点

  • FMR与BF正相关(r=0.886,p<0.001),与SUVmax(r=-0.547,p=0.003)和TTP(r=-0.462,p=0.015)负相关。
  • 放化疗后,反应者的BF和FMR显著高于非反应者(42.05±16.47 vs 27.48±8.55,p=0.007;3.18±1.15 vs 1.84±0.65,p=0.001)。
  • 低FMR患者OS和PFS更差,FMR是OS(p=0.026)和PFS(p=0.014)的独立预测因素。

核心结论

  • 低FMR所显示的血流-代谢不匹配在预测食管鳞状细胞癌放化疗敏感性和预后方面显示出良好潜力。

研究设计与样本

  • 前瞻性研究,纳入27例经病理证实的食管鳞状细胞癌患者,在根治性放化疗前使用独立成像系统行灌注CT和18F-FDG PET/CT。

主要发现

  • 中位总生存期(OS)为18个月,中位无进展生存期(PFS)为11.6个月。
  • FMR与BF呈显著正相关(r=0.886,p<0.001),与SUVmax(r=-0.547,p=0.003)和TTP(r=-0.462,p=0.015)呈负相关;灌注参数与PET参数之间无显著相关性。
  • 放化疗后,14例(51.9%)为反应者,13例为非反应者;反应者BF和FMR显著高于非反应者(42.05±16.47 vs 27.48±8.55,p=0.007;3.18±1.15 vs 1.84±0.65,p=0.001)。
  • ROC曲线显示,FMR(AUC=0.846)预测治疗反应优于BF(AUC=0.802)。
  • 单因素Cox分析显示,所有影像参数中仅FMR与OS(p=0.015)和PFS(p=0.017)显著相关;FMR较低的患者生存较差。

关键数值与推荐

  • FMR定义为BF除以SUVmax。
  • 灌注参数包括血流量(BF)、血容量(BV)和达峰时间(TTP);代谢参数包括最大标准化摄取值(SUVmax)、代谢肿瘤体积(MTV)和总病灶糖酵解(TLG)。
  • 预测治疗反应时,FMR的AUC为0.846,BF的AUC为0.802。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Perfusion CT can offer functional information about tumor angiogenesis, and 18F-FDG PET/CT quantifies the glucose metabolic activity of tumors. This prospective study aims to investigate the value of biologically relevant imaging biomarkers for predicting treatment response and survival outcomes in patients with locally advanced esophageal squamous cell cancer (LA ESCC). METHODS: Twenty-seven patients with pathologically proven ESCC were included. All patients had undergone perfusion CT and 18F-FDG PET/CT using separate imaging systems before receiving definitive chemoradiotherapy (dCRT). The perfusion parameters included blood flow (BF), blood volume (BV), and time to peak (TTP), and the metabolic parameters included maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG). The flow-metabolism ratio (FMR) was defined as BF divided by SUVmax. Statistical methods used included Spearman's rank correlation, Mann-Whitney U test or two-sample t test, receiver operating characteristic (ROC) curve analysis, the Kaplan-Meier method, and Cox proportional hazards models. RESULTS: The median overall survival (OS) and progression-free survival (PFS) were 18 and 11.6 months, respectively. FMR was significantly positively correlated with BF (r = 0.886, p < 0.001) and negatively correlated with SUVmax (r = - 0.547, p = 0.003) and TTP (r = - 0.462, p = 0.015) in the tumors. However, there was no significant correlation between perfusion and PET parameters. After dCRT, 14 patients (51.9%) were identified as responders, and another 13 were nonresponders. The BF and FMR of the responders were significantly higher than those of the nonresponders (42.05 ± 16.47 vs 27.48 ± 8.55, p = 0.007; 3.18 ± 1.15 vs 1.84 ± 0.65, p = 0.001). The ROC curves indicated that the FMR [area under the curve (AUC) = 0.846] was a better biomarker for predicting treatment response than BF (AUC = 0.802). Univariable Cox analysis revealed that of all imaging parameters, only the FMR was significantly correlated with overall survival (OS) (p = 0.015) and progression-free survival (PFS) (p = 0.017). Specifically, patients with a lower FMR had poorer survival. Multivariable analysis showed that after adjusting for age, clinical staging, and treatment response, the FMR remained an independent predictor of OS (p = 0.026) and PFS (p = 0.014). CONCLUSIONS: The flow-metabolism mismatch demonstrated by a low FMR shows good potential in predicting chemoradiotherapy sensitivity and prognosis in ESCC.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Zhao K, Wang C, Mao Q, et al. The flow-metabolism ratio might predict treatment response and survival in patients with locally advanced esophageal squamous cell carcinoma. EJNMMI Res. 2020. PMID: 32472227. doi:10.1186/s13550-020-00647-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。